Fig. 4

Activin A does not reduce severity of established LIDs, a experimental design. Mice are injected with 6-OHDA and develop a lesion over a 3 week period, before receiving repeated l-Dopa injections to establish AIMs during the following 3 weeks. Based on the AIMs score (Pretest) animals are split into 2 even groups and are implanted with an osmotic micropump containing either activin A or vehicle. Daily l-Dopa injections continue and AIMs are scored every 3rd day for 120 min. Activin A did not alter global AIMs score over a testing period of 13 days (b), during the monitoring session on the last day (c) or as a combination of axial, limb and orolingual scores during the last testing session (d). All values represent the mean ± SEM (control n = 7; activin A n = 8)